Development and Validation of an Alternative HPLC-DAD Method for Cisplatin Analysis in Solution

Sevgi Sarigul Ozbek; Alkim Beste Saglam; Gülen Melike Demirbolat

doi:10.18596/jotcsa.1751672

Development and Validation of an Alternative HPLC-DAD Method for Cisplatin Analysis in Solution

Abstract

Cisplatin is a widely used chemotherapeutic agent, and its precise & accurate quantification in solutions is crucial because these methods could be further used for its determination in pharmaceutical formulations and biological matrices. Here, a novel, rapid, and reliable reversed-phase isocratic HPLC method was developed and validated for the determination of cisplatin in solution. The resolution was achieved using a C18 column as the stationary phase and a mixture of methanol:sodium dodecyl sulphate (MeOH:SDS, 0.5 mM, 30:70) with a flow rate of 0.5 mL/min as the mobile phase. The detection was carried out at 204 nm, and the analysis was completed within seven minutes. The validation of the proposed method, which is easy, fast, and does not require the use of any acid or base, was performed in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals (ICH Q2(R2)). Depending on the findings, the developed method showed high linearity over the concentration range of 20-150 μg/mL. The limit of detection (LOD) and limit of quantitation (LOQ) were determined to be 7.37 and 22.33 μg/mL, respectively. Compared with previously reported methods, the proposed method demonstrated superior performance, with a wider linear range and acceptable LOD and LOQ. The system suitability parameters, including retention time, number of plates, height equivalent of a theoretical plate (HETP), area, tailing, and resolution, were evaluated. According to the obtained results, the developed method showed excellent chromatographic performance, characterized by high resolution, acceptable tailing, and a short analysis time.

Keywords

References

1. Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature [Internet]. 1965 Feb 1;205(4972):698–9. Available from: .
2. Dasari S, Bernard Tchounwou P. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol [Internet]. 2014 Oct 5;740(7):364–78. Available from: .
3. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov [Internet]. 2005 Apr 24;4(4):307–20. Available from: .
4. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene [Internet]. 2012 Apr 12;31(15):1869–83. Available from: .
5. Turoňová D, Krčmová LK, Vošmik M, Melichar B, Švec F. Using HPLC for the determination of platinum drugs in biological matrixes after derivatization with diethyldithiocarbamate. J Sep Sci [Internet]. 2023 Oct 28;46(19):2300392. Available from: .
6. Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: A review for chemists. Dalt Trans [Internet]. 2018 May 15;47(19):6645–53. Available from: .
7. Ye L, Xiang M, Lu Y, Gao Y, Pang P. Electrochemical determination of cisplatin in serum at graphene oxide/multi-walled carbon nanotubes modified glassy carbon electrode. Int J Electrochem Sci [Internet]. 2014 Mar 1;9(3):1537–46. Available from: .
8. Corte Rodríguez M, Álvarez-Fernández García R, Blanco E, Bettmer J, Montes-Bayón M. Quantitative evaluation of cisplatin uptake in sensitive and resistant individual cells by single-cell ICP-MS (SC-ICP-MS). Anal Chem [Internet]. 2017 Nov 7;89(21):11491–7. Available from: .

9. Lim SY, Low ZE, Tan RPW, Lim ZC, Ang WH, Kubota T, et al. Single-cell and bulk ICP–MS investigation of accumulation patterns of Pt-based metallodrugs in cisplatin-sensitive and -resistant cell models. Metallomics [Internet]. 2022 Dec 8;14(12):mfac085. Available from: .
10. Basotra M, Singh SK, Gulati M. Development and validation of a simple and sensitive spectrometric method for estimation of cisplatin hydrochloride in tablet dosage forms: Application to dissolution studies. ISRN Anal Chem [Internet]. 2013 Sep 19;2013(1):936254. Available from: .
11. Munawar Hayat M, Sohail M, Ashraf M. Spectrophotometric determination of cisplatin, carboplatin and oxaliplatin in pure and injectable dosage forms. Biomed Res [Internet]. 2019;30(4):557–62. Available from: .
12. Kostova I. Platinum complexes as anticancer agents. Recent Pat Anticancer Drug Discov [Internet]. 2006 Jan 1;1(1):1–22. Available from: .
13. Burns RB, Embree L. Validation of high-performance liquid chromatographic assay methods for the analysis of carboplatin in plasma ultrafiltrate. J Chromatogr B Biomed Sci Appl [Internet]. 2000 Jul 21;744(2):367–76. Available from: .
14. Khuhawar M., Lanjwani S., Memon S. High-performance liquid chromatographic determination of cisplatin as platinum(II) in a pharmaceutical preparation and blood samples of cancer patients. J Chromatogr B Biomed Sci Appl [Internet]. 1997 May 23;693(1):175–9. Available from: .
15. Pierre PV, Wallin I, Eksborg S, Ehrsson H. Quantitative liquid chromatographic determination of intact cisplatin in blood with microwave-assisted post-column derivatization and UV detection. J Pharm Biomed Anal [Internet]. 2011 Aug 25;56(1):126–30. Available from: .
16. Zhao Z, Tepperman K, Dorsey JG, Elder RC. Determination of cisplatin and some possible metabolites by ion-pairing chromatography with inductively coupled plasma mass spectrometric detection. J Chromatogr B Biomed Sci Appl [Internet]. 1993 May 19;615(1):83–9. Available from: .
17. Tezcan S, Özdemir F, Turhal S, İzzettin FV. High performance liquid chromatographic determination of free cisplatin in different cancer types. Sch Res Libr Der Pharma Chem [Internet]. 2013;5(5):169–74. Available from: .
18. Ermer J, Nethercote PW. Method validation in pharmaceutical analysis: A guide to best practice [Internet]. Wiley; 2025. Available from: .
19. Validation of analytical procedures Q2(R2). Available from: .
20. Salas S, Mercier C, Ciccolini J, Pourroy B, Fanciullino R, Tranchand B, et al. Therapeutic drug monitoring for dose individualization of cisplatin in testicular cancer patients based upon total platinum measurement in plasma. Ther Drug Monit [Internet]. 2006;28(4):532–9. Available from: .
21. Kaushik KH, Sripuram VK, Bedada S, Reddy NY, Priyadarshini GI, Devarakonda KR. A simple and sensitive validated HPLC method for quantitative determination of cisplatin in human plasma. Clin Res Regul Aff [Internet]. 2010 Mar 21;27(1):1–6. Available from: .
22. Karbownik A, Szałek E, Urjasz H, Głęboka A, Mierzwa E, Grześkowiak E. The physical and chemical stability of cisplatin (Teva) in concentrate and diluted in sodium chloride 0.9%. Współczesna Onkol [Internet]. 2012;5:435–9. Available from: .
23. Toro-Córdova A, Ledezma-Gallegos F, Mondragon-Fuentes L, Jurado R, Medina LA, Pérez-Rojas JM, et al. Determination of liposomal cisplatin by high-performance liquid chromatography and its application in pharmacokinetic studies. J Chromatogr Sci [Internet]. 2016 Jul 1;54(6):1016–21. Available from: .
24. Talari S, Anuradha V, Prathyusha AK. New validated RP-HPLC method for cisplatin and topotecan in API and vaccine form and its stress studies. Int J Res Pharm Sci. 2021;12(1):808–14.
25. Arenas M, Martín J, Santos JL, Aparicio I, Fernández-Sanfrancisco O, Alonso E. Comparison of different techniques for the determination of platinized cytostatic drugs in urine samples. Molecules [Internet]. 2022 Nov 23;27(23):8139. Available from: .
26. Ariöz F, Yalçin G, Dölen E. Determination of cisplatin, transplatin and amminetri-chloroplatinate by high performance liquid chromatography in one run using 4-methyl-2-thiouracil as derivatizing agent. Chromatographia [Internet]. 1999 May;49(9–10):562–6. Available from: .
27. Bosch ME, Sánchez AJR, Rojas FS, Ojeda CB. Analytical methodologies for the determination of cisplatin. J Pharm Biomed Anal [Internet]. 2008 Jul 15;47(3):451–9. Available from: .
28. Berners-Price SJ, Appleton TG. The chemistry of cisplatin in aqueous solution. In: Platinum-Based Drugs in Cancer Therapy [Internet]. Totowa, NJ: Humana Press; 2000. p. 3–35. Available from: .
29. El-Khateeb M, Appleton TG, Charles BG, Gahan LR. Development of HPLC conditions for valid determination of hydrolysis products of cisplatin. J Pharm Sci [Internet]. 1999 Mar 1;88(3):319–26. Available from: .
30. Ruiz‐Ángel MJ, García‐Álvarez‐Coque MC. Comparison of the performance of non‐ionic and anionic surfactants as mobile phase additives in the RPLC analysis of basic drugs. J Sep Sci [Internet]. 2011 Mar 17;34(6):623–30. Available from: .
31. Tereba-Mamani CJ, Blázquez-Mateu M, Ruiz-Angel MJ, García-Alvarez-Coque MC. The role of the cation and anion in aqueous liquid chromatography with sodium dodecyl sulphate and imidazolium-based ionic liquids as mobile phase reagents. Anal Chim Acta [Internet]. 2024 Aug 22;1318(6):342942. Available from: .

Details

Primary Language

English

Subjects

Instrumental Methods, Analytical Chemistry (Other)

Journal Section

Research Article

Authors

Sevgi Sarigul Ozbek ^*
0000-0002-0676-2415
Türkiye

Alkim Beste Saglam
Türkiye

Gülen Melike Demirbolat
0000-0001-5621-5818
Türkiye

Publication Date

March 23, 2026

Submission Date

July 26, 2025

Acceptance Date

February 10, 2026

Published in Issue

Year 2026 Number: 2026-1

DOI

https://doi.org/10.18596/jotcsa.1751672

IZ

https://izlik.org/JA79FX65SF

Cite

RIS / Bibtex

APA

Sarigul Ozbek, S., Saglam, A. B., & Demirbolat, G. M. (2026). Development and Validation of an Alternative HPLC-DAD Method for Cisplatin Analysis in Solution. Journal of the Turkish Chemical Society Section A: Chemistry, 2026-1, 1-7. https://doi.org/10.18596/jotcsa.1751672

AMA

1.Sarigul Ozbek S, Saglam AB, Demirbolat GM. Development and Validation of an Alternative HPLC-DAD Method for Cisplatin Analysis in Solution. JOTCSA. 2026;(2026-1):1-7. doi:10.18596/jotcsa.1751672

Chicago

Sarigul Ozbek, Sevgi, Alkim Beste Saglam, and Gülen Melike Demirbolat. 2026. “Development and Validation of an Alternative HPLC-DAD Method for Cisplatin Analysis in Solution”. Journal of the Turkish Chemical Society Section A: Chemistry, no. 2026-1: 1-7. https://doi.org/10.18596/jotcsa.1751672.

EndNote

Sarigul Ozbek S, Saglam AB, Demirbolat GM (March 1, 2026) Development and Validation of an Alternative HPLC-DAD Method for Cisplatin Analysis in Solution. Journal of the Turkish Chemical Society Section A: Chemistry 2026-1 1–7.

IEEE

[1]S. Sarigul Ozbek, A. B. Saglam, and G. M. Demirbolat, “Development and Validation of an Alternative HPLC-DAD Method for Cisplatin Analysis in Solution”, JOTCSA, no. 2026-1, pp. 1–7, Mar. 2026, doi: 10.18596/jotcsa.1751672.

ISNAD

Sarigul Ozbek, Sevgi - Saglam, Alkim Beste - Demirbolat, Gülen Melike. “Development and Validation of an Alternative HPLC-DAD Method for Cisplatin Analysis in Solution”. Journal of the Turkish Chemical Society Section A: Chemistry. 2026-1 (March 1, 2026): 1-7. https://doi.org/10.18596/jotcsa.1751672.

JAMA

1.Sarigul Ozbek S, Saglam AB, Demirbolat GM. Development and Validation of an Alternative HPLC-DAD Method for Cisplatin Analysis in Solution. JOTCSA. 2026;:1–7.

MLA

Sarigul Ozbek, Sevgi, et al. “Development and Validation of an Alternative HPLC-DAD Method for Cisplatin Analysis in Solution”. Journal of the Turkish Chemical Society Section A: Chemistry, no. 2026-1, Mar. 2026, pp. 1-7, doi:10.18596/jotcsa.1751672.

Vancouver

1.Sevgi Sarigul Ozbek, Alkim Beste Saglam, Gülen Melike Demirbolat. Development and Validation of an Alternative HPLC-DAD Method for Cisplatin Analysis in Solution. JOTCSA. 2026 Mar. 1;(2026-1):1-7. doi:10.18596/jotcsa.1751672